Navigation Links
Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Date:2/11/2008

Jean-Frederic Viret, Ph.D. Promoted to Vice President and Chief Financial

Officer; Richard P. Powers to Transition to Consultant Role

SOUTH SAN FRANCISCO, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today reported 2007 fourth quarter and year-end financial results and accomplishments and outlined its objectives for 2008 based on commercialization plans for FDA-approved Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system, as well as clinical development milestones for Adlea(TM), the company's long-acting, localized, non-opioid analgesic drug candidate.

"We are preparing on multiple fronts for a successful commercial introduction for Zingo in the second quarter by driving product demand through multiple initiatives and direct contact with our target customers," said John P. McLaughlin, chief executive officer of Anesiva. "We also have a very active clinical program with Adlea that includes two ongoing Phase 2 trials in post-surgical pain as well as plans to advance into two Phase 3 registration trials in post-surgical indications in the first half of 2008."

Recent Highlights and Accomplishments

Anesiva continued to execute on its corporate, commercial and clinical milestones in late 2007 and early 2008:

Zingo

-- Hired sales force of 15 regional account managers (RAMs) and two

directors targeting key pediatric hospitals to commercialize Zingo for

the approved patient population (three to 18 years of age). The RAMs

completed training and went into their territories at the end of

January. The Anesiva sales force will focus their efforts on creating

demand by educating nurses and physici
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Anesiva Appoints Daniel Janney to Board of Directors
2. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
3. Anesiva Announces Completion of Common Stock Offering
4. Anesiva Raises $45 Million in Common Stock Offering
5. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
6. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
7. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
8. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
9. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
10. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
11. Elekta Announces First Volumetric Modulated Arc Therapy Cancer Treatment at Royal Marsden Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Francisco, CA (PRWEB) July 10, 2014 ... family closer together. The Archer Family purchased a ... contained within DNA, but ended up with a lifetime ... discoveries contained within the family members’ DNA genuinely brought ... had decided to search deeper into genetic history and ...
(Date:7/10/2014)... POINT, Ind. , July 10, 2014 ... expanded its use of capnography for respiratory ... growing group of healthcare leaders in embracing ... measures how effectively patients are breathing and ... depression occurs. By measuring the amount of ...
(Date:7/10/2014)... --  Ceres, Inc . (Nasdaq: CERE ), ... results for the three months ended May 31, 2014 ... Ceres reported that the company and its customers have ... in Brazil, which concluded in June, despite dry and ... for part of the growing season. Yields of several ...
(Date:7/10/2014)... of psychiatric disorders has been extremely challenging because there ... are insufficient to cause disease. Now investigators reporting in ... Cell Stem Cell describe a strategy that ... with other risk factors or environmental exposures to affect ... a genetic variant that may predispose individuals to schizophrenia. ...
Breaking Biology Technology:Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9New strategy could uncover genes at the root of psychiatric illnesses 2
... 19 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX:,ARI), a ... of,antibody therapeutics, today announced that David Young, MD, ... at the Chinese Global,Financial Forum. Dr. Young will ... will be available prior to and following his ...
... ... WEST HAVEN, Conn., Oct. 19 Dr. Heather Coyle ... Haven have,developed a new method for preparing certain skeletal remains ... the,research the group is doing for the Smithsonian Institution. Obtaining ...
... Therapeutics Inc., a,Nutritional Therapeutics Innovation Company, today announced ... Wakeman as President. "Pilot has always had ... and dietary supplement areas with over 60 issued ... potential to rapidly move our,world class technologies and ...
Cached Biology Technology:ARIUS to present at Chinese Global Financial Forum 2800-Year-Old Mummies Aid Current Cold Cases: 2Pilot Therapeutics Announces New Executive Team with Extensive Experience Creating New Health and Nutrition Businesses 2
(Date:7/11/2014)... at the Department of Energy,s Oak Ridge National ... by R&D Magazine in recognition of the year,s ... the tremendous value of our National Labs," said ... at the National Labs continues to help our ... scientific and technological innovations necessary to remain globally ...
(Date:7/11/2014)... Bone and Mineral Research awarded Michael F. Holick, PhD, ... the 2014 Louis V. Avioli Award. Holick, a professor ... known for revolutionizing the understanding of vitamin D and ... honors a member of the American Society for Bone ... and mineral basic research. It is named for ASBMR,s ...
(Date:7/11/2014)... Cell scientists have set a "mouse TRAP" to capture ... a recent study published in the Journal of ... a technique called TRAP to extract cellular and genetic ... by scientists at the Rockefeller Institute for Medical Research ... the protein-making machinery, or ribosomes, of the cell type ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2
... Scientists propose developing an environmentally-friendly fungal spray that would ... a critical growth stage. This spray will contain ... and will have no side-effects on non-target organisms and ... therefore provide a quick, safe and effective means for ...
... the Technion Israel Institute of Technology, the ... have recently identified genes responsible for the positive ... drug Copaxone®. These findings may contribute to the ... Copaxone® was the first original Israeli drug ...
... -- A new book by researchers at the ... the mouse demonstrates a surprising similarity between mice and humans. ... by a team from the Hebrew University Bone Laboratory consisting ... Hajbi-Yonissi and Dr. Yankel Gabet. Also participating in the writing ...
Cached Biology News:New hope for horse lovers as effective control for killer ragwort is proposed 2Israeli scientists identify: Genes that affect responses of multiple sclerosis patients to copaxone 2Of mice and men: similarities between skeletons of both 2
... exciting product for cell-based kinetic assays and ... use of expensive HTS equipment, which lead ... assay development stage. The NOVOstar offers the ... well as any other assay suitable for ...
... measures mitochondria intactness and detects events ... Features and Benefits: Fast, ... isolated mitochondria and for assaying mitochondria ... reagents required for the detection of ...
... save space and organize gloves, ... other garb. They are the ... small parts used in labs, ... Open-slot design for easy cleaning. ...
... handy dispensers save space and ... hats, and other garb. They ... bins for small parts used ... Clear acrylic. Many other sizes ...
Biology Products: